New peptide inhibitors modulate the self-assembly of islet amyloid polypeptide residues 11–20 in vitro

 

Mao, Y., Yu, L., Yang, R., et al.

European Journal of Pharmacology 2017, vol:804, 102-110 doi: 10.1016/j.ejphar.2017.03.015

Abstract

The structural transition and misfolding of human islet amyloid polypeptide may cause a common metabolic disease Type 2 diabetes mellitus. Seventeen peptides have been synthesized, possessing different lengths, compositions, and peptide conformation. In this study, the mechanism of these peptides on inhibiting the formation of hIAPP11–20 amyloid fibrils was investigated using a conventional ThT fluorescence assay and microscale thermophoresis. The results showed that short peptides AT, SA, RF, KS, KT and KN, and cyclic peptides cyclic-KS, cyclic-KT and cyclic-KN displayed considerable inhibitory effect on hIAPP11–20 fibril formation and a strong affinity for hIAPP11–20. The detailed investigation indicated that the phenylalanine residue and some special peptide composition significantly inhibit amyloid formation. The peptide conformation of the designed peptide inhibitors may also play an important role. Microscale thermophoresis quantified the binding affinities between hIAPP11–20 and the peptides; and revealed that high affinity binding more likely leads to inhibiting fibril formation of hIAPP11–20 and vice versa, which is in accordance with the results from the ThT assays. These findings suggest a feasible model of peptide inhibitor design for inhibiting amyloid formation. In addition, microscale thermophoresis was proven as a promising rapid method for preliminarily screening inhibitors of hIAPP11–20.

View Publication

Topics: Aggregation, Dimerization & oligomerization, Monolith – Microscale Thermophoresis, Peptides, Publications, Thermodynamics, Neurodegenerative diseases

 

 

Previous Article
Structural basis of small molecule targetability of monomeric tau protein
Structural basis of small molecule targetability of monomeric tau protein

Up next
Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of ß-amyloid peptide
Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of ß-amyloid peptide

Characterize the molecular mechanisms of neurodegenerative diseases

Learn how